Cargando…
Why is it critical to achieve a deep molecular response in chronic myeloid leukemia?
The primary goal of tyrosine kinase inhibitor (TKI) therapy for patients with chronic myeloid leukemia is survival, which is achieved by the vast majority of patients. The initial response to therapy provides a sensitive measure of future clinical outcome. Measurement of BCR-ABL1 transcript levels u...
Autor principal: | Branford, Susan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716360/ https://www.ncbi.nlm.nih.gov/pubmed/33054104 http://dx.doi.org/10.3324/haematol.2019.240739 |
Ejemplares similares
-
Measurable residual disease in chronic myeloid leukemia
por: Branford, Susan, et al.
Publicado: (2022) -
Genomic Mechanisms Influencing Outcome in Chronic Myeloid Leukemia
por: Fernandes, Adelina, et al.
Publicado: (2022) -
Initial Rate of BCR::ABL1 Decline for Response Prediction in Chronic Myeloid Leukemia
por: Branford, Susan
Publicado: (2022) -
Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients
por: Estrada, Natalia, et al.
Publicado: (2021) -
Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia
por: Annunziata, Mario, et al.
Publicado: (2020)